References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2017-18-44-55

medsovet-2031

Research Article

Бронхиальная астма

Bronchial asthma

РОЛЬ АНТИЛЕЙКОТРИЕНОВЫХ ПРЕПАРАТОВ В ДОСТИЖЕНИИ КОНТРОЛЯ БРОНХИАЛЬНОЙ АСТМЫ

ROLE OF ANTILEUKOTRIENE DRUGS IN ACHIEVEMENT OF BRONCHIAL ASTHMA CONTROL

Ненашева

Н. М.

Nenasheva

N. M.

д.м.н., профессор

MD, Prof.

Российская медицинская академия непрерывного профессионального образованияРоссияRussian Medical Academy of Continuous Professional EducationRussian Federation

2017

03112017

0184455

2017

Ненашева Н.М.

Nenasheva N.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/2031

Бронхиальная астма (БА) – распространенное хроническое заболевание, является гетерогенным по своей природе и вариабельным по своему течению. Гетерогенность астмы проявляется в отношении возраста дебюта, триггеров, паттерна воспаления, тяжести клинических проявлений и ответа на терапию. Цистеиниловые лейкотриены играют важную роль в патогенезе БА и аллергического ринита (АР), поэтому антагонисты рецепторов цистеиниловых лейкотриенов зарекомендовали себя как эффективные препараты в контролирующей терапии астмы, особенно некоторых фенотипов. Эта обзорная статья посвящена современной роли монтелукаста в лечении БА.

Bronchial asthma (BA) is a common chronic disease heterogeneous in nature and variable in its course. Heterogeneity in asthma is manifested in relation to the age of the onset, triggers, pattern of inflammation, severity of clinical manifestations and response to therapy. Cysteinyl leukotrienes play an important role in the pathogenesis of asthma and allergic rhinitis (AR), therefore, antagonists of leukotriene receptors approved themselves as effective drugs in controlling asthma therapies, particularly for some phenotypes. This review article is devoted to the modern role of Montelukast in asthma treatment.

бронхиальная астмафенотипы астмымонтелукаст

bronchial asthmaphenotypes of asthmaMontelukast

References1

Anandan C, Nurmatov U, van Schayck OCP, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy, 2010, 65: 152-167.

Thomas AE. Platts-Mills The Allergy Epidemics: 1870– 2010. J Allergy Clin Immunol, 2015, 136(1): 3-13.

Национальная программа «Бронхиальная астма у детей . Стратегия лечения и профилактика», 2017 [электронный ресурс] http://nphcd.ru/ wp-content/uploads/2017/05/103640_old.pdf (дата обращения 24.08.2017).

Chuchalin AG, Khaltaev N, Аntonov N et al. Chronic Respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of COPD, 2014, 9: 963-974.

GINA 2014. www.ginasthma.org.

Drazen JM. A step toward personalized asthma treatment. N Engl J Med, 2011, 365(13): 1245-1246. doi: 1056/NEJMe1102469.

Tintinger GR, Feldman C, Theron AJ, Anderson R. Montelukast: more than a cysteinyl leukotriene receptor antagonist? Scientific World Journal, 2010, 10: 2403-2413. doi: 10.1100/tsw.2010.229.

Miligkos M, Bannuru RR, Alkofide H, Kher SR, Schmid CH, Balk EM. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents, a systematic review and meta-analysis. Ann Intern Med, 2015, 163(10): 756-767. doi: 10.7326/M15-1059.

Zhang HP, Jia CE, Lv Y, Gibson PG, Wang G. Montelukast for prevention and treatment of asthma exacerbations in adults: systematic review and meta-analysis. Allergy Asthma Proc, 2014, 35(4): 278-287. doi: 10.2500/aap.2014.35.3745.

Ненашева Н.М. Настоящее и будущее антагонистов лейкотриеновых рецепторов в терапии бронхиальной астмы и аллергических заболеваний. Эффективная фармакотерапия. Пульмонология и оториноларингология, 2012, 4: 10-17.

Федеральные клинические рекомендации по диагностике и терапии бронхиальной астмы, пересмотр 2016 г. [электронный ресурс] http:// spulmo.ru/obshchestvo/news/news-812 (дата обращения 24.08.2017).

Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev, 2012, 16(5): CD002314.

Price D, Musgrave S, Shepstone L et al. Leuko triene Antagonists as First-Line or Add-on Asthma-Controller Therapy. NEJM, 2011, 364: 1695-1707.

Drazen JM, Yandava CN, Dubé L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet, 1999, 22(2): 168–70. doi: 10.1038/9680.

Bousquet J, Khaltaev N, Cruz A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update. Allergy, 2008, 63(Suppl 86): 1-160.

Clatworthy J, Price D, Ryan D, Haughney J, Horne R. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J, 2009, 18: 300-305.

Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs, 2007, 67: 887-901. doi: 10.2165/00003495-200767060-00005.

Price DB, Swern A, Tozzi CA, Philip G, Polos P. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy, 2006, 61(6): 737742. doi: 10.1111/j.1398-9995.2006.01007.x.

Virchow JC, Mehta A, Ljungblad L, Mitfessel H. A subgroup analysis of the MONICA study: a 12-month, open-label study of add-on montelukast treatment in asthma patients. J Asthma, 2010, 47: 986993. doi: 10.1080/02770903.2010.494753.

Frick OL, German DF, Mills J. Development of allergy in children. I. Association with virus infections. J Allergy Clin Immunol, 1979, 63(4): 228-241.

Johnston NW, Johnston SL, Duncan JM, et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol, 2005, 115: 132-138.

Seymour ML, Gilby N, Bardin PG et al. Rhinovirus infection increases 5-lipoxygenase and cyclooxygenase-2 in bronchial biopsy specimens from non-atopic subjects. J Infect Dis, 2002, 185: 540-544.

Gentile DA, Fireman P, Skoner DP. Elevations of local leukotriene C4 levels during viral upper respiratory tract infections. Ann Allergy Asthma Immunol, 2003, 91: 270-274.

van Schaik, SM, Tristram, DA, Nagpal, IS et al. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol, 1999, 103: 630-636.

Johnston NW, Mandhane PJ, Dai J et al. Attenua tion of the September epidemic of asthma exacerbations in children: a rando mized, controlled trial of montelukast added to usual therapy. Pediatrics, 2007, 120: e702-712.

Bisgaard H, Zielen S, Garcia-Garcia ML et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med, 2005, 171: 315-322.

Peng WS, Chen X, Yang XY, Liu EM. Systematic review of montelukast’s efficacy for preventing post-bronchiolitis wheezing. Pediatr Allergy Immunol, 2014, 25(2): 143-150.

Matsuse H, Fukahori S, Tsuchida T et al. Effects of a short course of pranlukast combined with systemic corticosteroid on acute asthma exacerbation induced by upper respiratory tract infection. J Asthma, 2012, 49(6): 637-641.

Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med, 1994, 149: 953-959.

Anderson SD, Daviskas E. The mechanism of EIA is… J Allergy Clin Immunol, 2000, 106(3): 453-9.

Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Immunol, 2006, 97: 98–104. doi: 10.1016/S1081-1206(10)61377-4.

Peroni DG, Pescollderungg L, Sandri M, Chinellato I, Boner AL, Piacentini GL. Time-effect of montelukast on protection against exercise-induced bronchoconstriction. Respir Med, 2011, 105(12): 1790-1807. doi: 10.1016/j.rmed.2011.08.007.

De Benedictis FM, Del Giudice MM, Forenza N et al. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J, 2006, 28: 291-295.

To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet L-P. Global Asthma Prevalence in Adults. BMC Public Health, 2012, 12(204).

Peters JM, Avol E, Navidi W et al. A study of twelve Southern California communities with differing levels and types of air pollution: I. Prevalence of respiratory morbidity. Am J Respir Crit Care Med, 1999, 159: 760.

Leson S, Gershwin ME. Risk factors for asthmatic patients requiring intubation. I. Observations in children. J Asthma, 1995, 32: 285-294.

Gerald LB, Gerald JK, Gibson L et al. Changes in environmental tobacco exposure and asthma morbidity among urban school children. Chest, 2009, 135: 911-916.

Kontogianni K, Bakakos P, Kostikas K et al. Levels of prostaglandin E2 and Cysteinyl-leukotrienes in sputum supernatant of patients with asthma: the effect of smoking. Clinical & Experimental Allergy, 2012, 43: 616-624.

Gaki E, Papatheodorou G, Ischaki E et al. Leukotri ene E(4) in urine in patients with asthma and COPD–the effect ofsmoking habit. Respir Med, 2007, 101: 826-832.

Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med, 2007, 175: 783-790.

Price D, Popov T, Bjermer L et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol, 2013, 131: 763-771.

Holguin F, Bleecker ER, Busse WW et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol, 2011, 127: 1486-1493.

Giouleka P, Papatheodorou G, Lyberopoulos P et al. Body mass index is associated with leukotriene inflammation in asthmatics. European Journal of Clinical Investigation, 2011, 41(1): 30-38.

Peters-Golden M, Swern A, Bird S et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J, 2006, 27: 495-503.

Sutherland ER, Camargo CA, Jr, Busse WW et al. Comparative effect of body mass index on response to asthma controller therapy. Allergy Asthma Proc, 2010, 31(1): 20-25. doi: 10.2500/aap.2010.31.3307.

Ledford DK, Wenzel SE, Lockey RF. Aspirin or other nonsteroidal inflammatory agent exacerbated asthma. J Allergy Clin Immunol Pract, 2014, 2(6): 653657.

Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE investigators. European network on aspirin-induced asthma. Eur. Respir. J., 2000, 16(3): 432-436.

Dahlén SE, Malmström K, Nizankowska E, Dahlén B, Kuna P, Kowalski M et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med, 2002, 165: 9-14.

Mastalerz L, Nizankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene re ceptor antagonist. Eur J Clin Invest, 2002, 32(12): 949-955.

White A, Ta V. Survey-defined patient experiences with aspirin-exacerbated respiratory disease (AERD). J Allergy Clin Immunol Pract, 2015, 3: 711-718.

Ye YM, Kim SH, Hur GY, Kim JH, Park JW, Shim JJ, Jung KS, Lee HY, Park HS, PRANA Group Addition of Montelukast to Low-dose inhaled corticosteroid leads to fewer exacerbations in older patients than medium-dose inhaled corticosteroid Monotherapy. Allergy, Asthma Immunol Res, 2015, 7(5): 440-448. doi: 10.4168/aair.2015.7.5.440.

Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska

A, Jarzab J. Montelukast as an add-on therapy to

in ha led corticosteroids in the treatment of severe asthma in elderly patients. J Asthma, 2012, 49: 530-534.

Scichilone N, Ventura MT, Bonini M, Braido F, Bucca C, Caminati M et al. Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. Clin Mol Allergy, 2015, 13(1): 7.

Mechiche H, Naline E, Candenas L, Pinto FM, Birembault P, Advenier C, Devillier P. Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites. Clin Exp Allergy, 2003, 33(7): 887-894.

Nakaji H, Petrova G, Matsumoto H, Iwata T, Ito I, Oguma T et al. Effects of 24-week add-on treatment with ciclesonide and montelukast on small airways inflammation in asthma. Ann Allergy Asthma Immunol, 2013, 110(3): 198-203.

Zeidler MR, Kleerup EC, Goldin JG, Kim HJ, Truong DA, Simmons MD et al. Montelukast improves regional air-trapping due to small airways obstruction in asthma. Eur Respir J, 2006, 27(2): 307-315.

Fritscher LG, Rodrigues MT, Zamel N, Chapman KR. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respir Med, 2009, 103(2): 296–300.

Spahn JD, Covar RA, Jain N, Gleason M, Shimamoto R, Szefler SJ et al. Effect of montelukast on peripheral airflow obstruction in children with asthma. Ann Allergy Asthma Immunol, 2006, 96(4): 541-549.

Miligkos M, Bannuru RR, Alkofide H, Kher SR, Schmid CH, Balk EM. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adoles cents, a systematic review and meta-analysis. Ann Intern Med, 2015, 163(10): 756-767. doi: 10.7326/ M15-1059.

Nwokoro C, Pandya H, Turner S, Eldridge S, Griffiths CJ, Vulliamy T et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial. Lancet Respir Med, 2014, 2(10): 796-803.

Сидоренко И.В., Захаржевская Т.В. Эффективность и безопасность монтелукаста при лечении бронхиальной астмы и аллергического ринита в рутинной клинической практике: результаты проспективной многоцентровой наблюдательной программы. РАЖ, 2016, 2: 44-53.

The authors declare that there are no conflicts of interest present.